Skip to NavigationSkip to content

Pharma news from Datamonitor

Published on 17/05/07 at 11:43am

Meda and Ethypharm collaborate on NSAID

Meda and Ethypharm have signed an exclusive 15-year agreement for an innovative NSAID product which will avoid gastrointestinal problems, according to the companies.

The companies believe that the combination of omeprazole (a proton pump inhibitor) and ketoprofen (NSAID) in one pill will avoid the gastrointestinal problems which are commonly associated with non-steroidal anti-inflammatory drugs (NSAID).

The agreement includes most European markets, including Germany, Spain, and the UK, and a product registration application has been submitted. Meda is paying E2 million after signing for the marketing rights, and will pay up to an additional E5 million in milestone payments when authorities approve registration and when specified sales levels are reached. No additional milestone payments will be made after sales reach E55 million.

Anders Lonner, Meda's CEO, said: "This new product will greatly aid patients who currently need two medications to avoid side effects from using NSAIDs. The agreement between Meda and Ethypharm fortifies Meda's position within the high-priority pain and inflammation therapy area - an area in which Meda already holds a strong position with several well-established products."


Bristol-Myers and Isis to collaborate on heart drugs

Bristol-Myers Squibb and Isis Pharmaceuticals have agreed to collaborate on novel antisense drugs for the prevention and treatment of cardiovascular disease in a deal worth up to $192 million.

Bristol-Myers Squibb will pay Isis a $15 million upfront licensing fee, and will provide Isis with at least $9 million in research funding over a period of three years. Isis will also receive up to $168 million in milestone payments. Bristol-Myers Squibb will also pay Isis royalties on sales of products resulting from the collaboration.

The therapies developed by the companies will target proprotein convertase subtilisin kexin 9 (PCSK9), which helps regulate the amount of cholesterol in the bloodstream. As part of the collaboration, Isis has licensed to Bristol-Myers Squibb exclusive access to its PCSK9 research program.

While Bristol-Myers Squibb will fund all activities under the collaboration, both companies will be responsible for preclinical development. Bristol-Myers Squibb will be responsible for clinical development, regulatory, and commercialization activities.

In addition, Bristol-Myers Squibb will work with Isis to identify follow-on PCSK9 antisense drugs with advanced antisense chemistries that may offer even greater potency and oral bioavailability.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches